tirzepatide and semaglutide tablets Weekly GLP-1 Injection vs Daily Oral: – PlexusDx Comparing Oral and Injectable Forms

14% body weight regained within one year of stopping tirzepatide 14% body weight regained within one year of stopping tirzepatide Other reputable clinical studies have been consistent in finding that patients experience significant weight regain* when they discontinue these medications.* The drawbacks of a one-size-fits-all approach Programs that promote GLP-1 deprescribing often employ a one-size-fits-all strategy including the diet used as a part of their program

Contact us today to schedule a consultation and take the first step towards a healthier, more fulfilling life with Semaglutide

Reduction of Cardiovascular Risk in Type 2 Diabetes: Studies have shown that semaglutide may help reduce the risk of major cardiovascular events (like heart attack or stroke) in individuals with type 2 diabetes who also have established cardiovascular disease (CVD)

In comparison, the subcutaneously administered once-weekly semaglutide CVOT, SUSTAIN 6 has shown superiority over placebo with a significant 26% risk reduction for MACE [19]